TPO and autoimmune thrombocytopenic purpura: Overall, TPO-RAs represent a paradigm shift in the second-line treatment of ITP, and there is evidence that some patients may be switched to an alternative TPO-RA as third-line treatment before the use of other treatment approaches such as invasive splenectomy [30,57,58].